Milestone Pharmaceuticals (MIST) Operating Leases (2019 - 2026)

Milestone Pharmaceuticals (MIST) has reported Operating Leases for 8 consecutive years, with $192000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 70.05% year-over-year to $192000.0; the trailing twelve-month figure through Jun 2026 stood at $192000.0 (down 70.05% YoY), and the FY2025 full-year result was $539000.0, down 38.33% from the prior year.
• Operating Leases slipped to $192000.0 in Q2 2026 per MIST's latest filing, from $366000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $2.1 million in Q3 2022 and bottomed at $192000.0 in Q2 2026.
• Historically, Operating Leases has averaged $1.0 million across 5 years, with a median of $938000.0 in 2024.
• The sharpest annual moves came in 2023 and 2026: Operating Leases jumped 350.26% in 2023, then slumped 70.05% in 2026.
• Over 5 years, Operating Leases stood at $2.0 million in 2022, then declined by 27.0% to $1.5 million in 2023, then slumped by 40.01% to $874000.0 in 2024, then plunged by 38.33% to $539000.0 in 2025, then sank by 64.38% to $192000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $192000.0, $366000.0, and $539000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.